GTCB..............................................................
Like biopearl I am a very long term holder of this stock who has suffered the slings and arrows of GTC's outrageous fortune. Despite the sad state of the PPS, I have never lost sight of the significance of their platform and its potential to improve medicine and be profitable. Throwing in my cards and giving up for a few pennies is not going to happen.
Did I mentioned I had learned of events that could possibly turn GTC into a multibillion dollar company?? Well this is what I am talking about. As stated in earlier posts I feel Atryn's (AT) greatest benefit is going to be in treating thrombotic strokes (TS) and heart attacks (AMI). With appologies to biopearl and the rest of the MDs and physiologists some clarification. TSs and AMIs are caused by interuption of the blood supply to areas of the brain or heart usually caused by atherosclerosis. Of importance in both conditions is the fact that area of cells which end up dying greatly exceeds the area in which the blood flow was lost. Thats right, more brain or heart is lost than would be predicted by merely mapping out the vessel blocked. So what happens?? In a nutshell the cells in the oxygen deprived area send out protein messengers which trigger apoptosis (cell suicide) in the surrounding areas making the clinical condition much worse.
At present TS and AMIs are treated with TPAs (clot busters) which biopearl can tell you more about. Anyway they can clear the obstruction in some cases if used early enough (only in about 3% of TS), but they do little to effect the apoptosis problem.
So where does Atryn (AT) enter the equation?? There is an accumulating body of evidence AT can block the signaling mechanisms which result in the apoptosis. Last year in Nov and paper in Stroke by Dr. O Cuomo et al from Naples It. Reported treating rats and mice, in which blood flow to area of the brain was interupted, with AT. They used AT intravenously at three and six after oxygen deprevation. AT was very effective at improving neurological function and mortality. I know what you are thinking,,,"these are only rats and mice". Well due to the primative nature of this problem and the fact the basic design of the physiology of the nervous system is so consistant that most basic nerve physiology has been worked out using Squid neurons,, it is extremely unlikely Cuomo's results would be different in humans.
Any way I have corresponded with Dr. Cuomo and he has told me they are planning to use AT to treat stroke patients. At present they are in final revision of their clinical protocol. This is not an EMEA trial. Non the less I anticipate they will be sucessful and they will publish their results. Because of the importance of this work I imagine their will be considerable publicity, as well as overwhelming political pressure to make this treatment available....
":>) JL
AI
Market Data 
Markets 
